COVID-19 vaccine – pharmaceutical daily

October 4, 2023 Off

Moderna’s combo vaccine shows strong immunogenicity against influenza and COVID-19

Moderna announced Wednesday positive results from a clinical trial of mRNA-1083, its combination mRNA combination flu/COVID vaccine.

November 14, 2022 Off

Moderna’s biovalent booster candidates meet primary endpoint of superiority against Omicron variants in trai

By Dino Mustafić

Moderna said Monday that both of its bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger a superior antibody response compared…

April 20, 2022 Off

Moderna: Clinical update on bivalent COVID-19 booster platform

By Author

Moderna has announced new clinical data on its bivalent COVID-19 booster platform including data on the company’s first bivalent booster candidate, mRNA-1273.211, which includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants of concern including Omicron.

April 14, 2022 Off

Valneva’s Inactivated Covid-19 Vaccine Gets CMA in UK

By Author

The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Valneva’s inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age.